Fluid

bioAffinity Technologies News Update

Retrieved on: 
木曜日, 5月 2, 2024
Research, Medical Devices, Health Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Physician, Nursing care plan, ATS, Chronic obstructive pulmonary disease, Lung cancer, Bronchoalveolar lavage, Conference, Baxter International, BIAF, Lung, Patient, Pulmonology, Marketing, Empathy, BAL, American Thoracic Society, Fluid, COPD, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.
  • Physicians outside of Texas are also signing up with our wholly owned subsidiary, Precision Pathology Laboratory Services, to order CyPath® Lung for their patients.
  • bioAffinity Technologies’ National Sales Director Dallas Coleman announced that Jackie Kennedy has joined the Company as Pulmonary Sales Executive for CyPath® Lung in the San Antonio/Austin market.
  • “Patients have told us how much they appreciate having a Patient Coach who can walk them through the collection process,” bioAffinity Technologies President and CEO Maria Zannes said.

New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged

Retrieved on: 
木曜日, 5月 2, 2024
Research, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Biotechnology, Managed Care, Health, Science, Stanford University, Mortality, Heart, Fluid, Heart failure, ADHF, American College, Clinical trial, GDMT, AUC, Hospital, Weight loss, Partnership, Area studies, Nursing, Patient, Reprieve, Physician, Acute, Circulatory system, Kaiser Permanente, Hyperkalemia, SDOH, HF, Division, Hypotension, Pharmaceutical industry

Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.

Key Points: 
  • Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.
  • In the TREAT-AHF study, the distribution of inpatient body weight change was similar to those reported from ADHERE nearly two decades ago.
  • Reprieve is partnering with industry-leading heart failure researchers and Truveta to understand and advance acute heart failure patient outcomes.
  • The clinical evidence from the TREAT-HF study demonstrates that heart failure decongestion management has not substantially changed in 20 years,” said Mark Pacyna, chief executive officer of Reprieve Cardiovascular.

FLUID INTERIORS ANNOUNCES STRATEGIC PARTNERSHIP WITH INTEGRATED TECHNOLOGY LEADER, LELCH

Retrieved on: 
月曜日, 4月 22, 2024
Culture, Creativity, Partnership, Workplace, Fluid, Industrial design

MINNEAPOLIS, April 22, 2024 /PRNewswire/ -- Fluid Interiors proudly announces its latest strategic partnership with Lelch, a leading integrated technology provider.

Key Points: 
  • MINNEAPOLIS, April 22, 2024 /PRNewswire/ -- Fluid Interiors proudly announces its latest strategic partnership with Lelch, a leading integrated technology provider.
  • "We are thrilled to announce our partnership with Lelch," said Berk Claiborne, President & CEO of Fluid Interiors.
  • "We are equally excited to embark on this journey with Fluid Interiors," stated Alex Lelchuk, President & Founder at Lelch.
  • The partnership between Fluid and Lelch will set a new standard for workplace design and technology integration.

Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

Retrieved on: 
水曜日, 4月 3, 2024
Cardiorenal syndrome, Congestion, DSR, Brussels Stock Exchange, Liver disease, Associate, RED, Patient, NYHA, Mortality, Cancer, Fluid, Heart failure, European Journal, Diuretic, Overload, Syndrome, Yale University, Pharmaceutical industry

The publication can be accessed here .

Key Points: 
  • The publication can be accessed here .
  • Dr. Jeffrey Testani, Associate professor at Yale University and senior author of the publication commented: “Cardiorenal syndrome is a major clinical challenge in heart failure with a clear unmet need for therapies to effectively and durably address congestion and cardio-renal dysfunction.
  • Currently the mainstay of therapy for sodium avidity and congestion are the loop diuretics, which actually worsen sodium avidity and cardiorenal syndrome.
  • Diuretic-resistant heart failure and cardiorneal syndrome are large and growing markets both in the US and rest of world, with the clear need for novel treatments that can improve clinical outcomes beyond loop diuretics.

Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy

Retrieved on: 
月曜日, 3月 25, 2024
Cardiorenal syndrome, Congestion, Myocardial infarction, DSR, Brussels Stock Exchange, Liver disease, Partnership, RED, Patient, 2.0, Blood urea nitrogen, Cancer, Fluid, Heart, Heart failure, Furosemide, EGFR, Safety, DSMB, Overload, Hyponatremia, Hypertension, Pharmaceutical industry

These final data support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome.

Key Points: 
  • These final data support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome.
  • Unlike loop diuretics which, on average, have a negative impact on renal function and diuretic response, DSR has again demonstrated its potential to restore renal health and control of volume status.
  • Dramatic improvement in diuretic response and stable kidney function: During the four-week DSR treatment period, all three patients maintained euvolemia without the need of loop diuretics.
  • In January 2024, the independent DSMB approved the start of the randomized MOJAVE cohort following review of the safety data reported from the non-randomized cohort.

Nordson Electronics Solutions to Demonstrate Plasma Treatment and Automated Fluid Dispensing Systems for Electronics Manufacturing at SEMICON China 2024

Retrieved on: 
水曜日, 3月 6, 2024
Hardware, Machinery, Packaging, Engineering, Consumer Electronics, Technology, Semiconductor, Manufacturing, Electronics, Fluid, Inspection, Plasma, Vantage

Nordson Electronics Solutions , a global leader in reliable electronics manufacturing technologies, will demonstrate their latest equipment for semiconductor manufacturing at SEMICON China 2024 , booth 3645.

Key Points: 
  • Nordson Electronics Solutions , a global leader in reliable electronics manufacturing technologies, will demonstrate their latest equipment for semiconductor manufacturing at SEMICON China 2024 , booth 3645.
  • View the full release here: https://www.businesswire.com/news/home/20240305040124/en/
    See the semiconductor manufacturing equipment from Nordson Electronics Solutions for plasma treatment and fluid dispensing demonstrated at SEMICON China 2024.
  • The MARCH FlexTRAK®-CD delivers high-throughput plasma processing of strip-type components for semiconductor manufacturing applications, such as leadframe or laminate strips presented in magazines.
  • The ASYMTEK Vantage® fluid dispensing system is used for applications in wafer-level packaging and panel-level packaging during semiconductor manufacturing.

bioAffinity Technologies News Update

Retrieved on: 
水曜日, 2月 21, 2024
Oncology, Health, Biometrics, Health Technology, General Health, Biotechnology, BIAF, American Thoracic Society, Medicine, Sputum, Research, Fluid, Cole, Conference, Chronic obstructive pulmonary disease, Nursing care plan, Lung, BAL, ATS, Human, Associate, Patient, Lung cancer, Bronchoalveolar lavage, COPD, Evidence-based practice, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
  • Lung Innovations Network’s multidisciplinary team focuses on affordable, innovative and individualized care by incorporating new technologies and research into an evidence-based practice.
  • National Sales Director Dallas Coleman announced that Cole Koeppen has joined bioAffinity Technologies as Pulmonary Sales Executive for CyPath® Lung in North Texas.
  • Bansal’s experience as both clinician and researcher demonstrates his commitment to innovative healthcare and the best possible outcome for his patients,” bioAffinity Technologies President and CEO Maria Zannes said.

International Journal of Fluid Engineering Publishes First Issue in Partnership with AIP Publishing

Retrieved on: 
月曜日, 3月 4, 2024
Engineering, Publishing, Research, Fluid, Eindhoven University of Technology, China University of Petroleum, Zhejiang Sci-Tech University, AIP, Canadian International Council, APL, American Institute of Physics, AIP Advances, Editorial, Partnership

MELVILLE, N.Y., March 4, 2024 /PRNewswire/ -- AIP Publishing is pleased to announce the International Journal of Fluid Engineering (IJFE), a peer-reviewed open access publication launched in partnership with the Fluid Engineering Institution of the Chinese Mechanical Engineering Society, has published its first issue .

Key Points: 
  • MELVILLE, N.Y., March 4, 2024 /PRNewswire/ -- AIP Publishing is pleased to announce the International Journal of Fluid Engineering (IJFE), a peer-reviewed open access publication launched in partnership with the Fluid Engineering Institution of the Chinese Mechanical Engineering Society, has published its first issue .
  • "It is with great enthusiasm that we embark on this journey, dedicated to the fascinating world of fluid mechanics in engineering," wrote Li in the journal's inaugural editorial .
  • The International Journal of Fluid Engineering is the latest in AIP Publishing's growing portfolio of open access titles, including AIP Advances and the APL family of journals — itself including the newly launched APL Quantum.
  • "AIP Publishing is excited to expand its open access publishing portfolio through the introduction of the International Journal of Fluid Engineering in partnership with the Chinese Mechanical Engineering Society, Hefei General Machinery Research Institute, Co., Ltd., and Zhejiang Sci-Tech University," said Dr. Penelope Lewis, AIP Publishing's Chief Publishing Officer.

Hello Down There: Squarespace Teams Up with Martin Scorsese for its 2024 Super Bowl Campaign

Retrieved on: 
水曜日, 2月 7, 2024
Heart, Creativity, Element, Fluid, Life, Super Bowl

NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Squarespace (NYSE: SQSP), the design-driven platform helping entrepreneurs build brands and businesses online, today revealed its 10th Super Bowl campaign directed by Martin Scorsese. The 30-second spot, titled 'Hello Down There', will run during the first half of Super Bowl LVIII on Feb. 11, 2024.

Key Points: 
  • NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Squarespace (NYSE: SQSP), the design-driven platform helping entrepreneurs build brands and businesses online, today revealed its 10th Super Bowl campaign directed by Martin Scorsese.
  • The 30-second spot, titled 'Hello Down There', will run during the first half of Super Bowl LVIII on Feb. 11, 2024.
  • Directed by the legendary Martin Scorsese, 'Hello Down There' is a humorous take on capturing the essence of human life consumed by the digital world.
  • "It's been an honor to work alongside the cinematic legend Martin Scorsese to bring this insight to life through his lens for our 10th Super Bowl campaign.

Carnival Corporation Announces Ambitious 2024 Greenhouse Gas Intensity Reduction Projections

Retrieved on: 
火曜日, 2月 6, 2024
Particulates, CCL, Nitrogen, Sheepdog trial, Noise, Methanol, International Maritime Organization, Carnival Corporation & plc, HVAC, Friction, Biofuel, LNG, GHG, Carbon, Hydrogen, Ship, Fluid, Weather, Electricity, LED, ALS, Renewable energy

MIAMI, Feb. 6, 2024 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK), the world's largest cruise company, today announced it is on pace to achieve an overall 18% reduction in greenhouse gas (GHG) emission intensity on a lower berth capacity basis in 2024 (compared to 2019) – just a few points shy of its 20% reduction goal originally targeted for 2030. By year end, the company expects to have reduced its GHG emission intensity by an impressive 42% on a lower berth capacity basis since its first benchmark in 2008. The company also expects this performance to put it ahead of the International Maritime Organization's (IMO) 2030 carbon intensity reduction timeline.

Key Points: 
  • MIAMI, Feb. 6, 2024 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK), the world's largest cruise company, today announced it is on pace to achieve an overall 18% reduction in greenhouse gas (GHG) emission intensity on a lower berth capacity basis in 2024 (compared to 2019) – just a few points shy of its 20% reduction goal originally targeted for 2030.
  • The company also expects this performance to put it ahead of the International Maritime Organization's (IMO) 2030 carbon intensity reduction timeline.
  • Carnival Corporation is executing on two parallel paths to achieve these significant reductions.
  • Since cruise ships generate their electricity from fuel, Carnival Corporation set out to uncover every area where energy can be saved and cut the amount of fuel used.